Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats

Molecular Neurobiology(2024)10.1007/s12035-024-04569-8Source: DataRank Database

Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats is a research paper published in Molecular Neurobiology (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.37)OA: greenTopics (72)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Rania Ahmed ORCID,M. Soriano,Aidan Powell ORCID,Panayotis K. Thanos ORCID,Heinz Steiner ORCID

Live enrichment

PubMed:39466575 OpenAlex:https://openalex.org/W4403827845

National Institutes of Health

Grant: 5R01DA046794-04

Serotonin receptors that potentiate addiction-related behavioral and molecular effects induced by methylphenidate plus SSRI exposure

NIDA NIH HHS

Grant: R01 DA046794

FWCI

0.37

Citation Percentile

0.6%

Citation Trend

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12143123/pdf/nihms-2081224.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s12035-024-04569-8.pdf

publisherhttps://link.springer.com/article/10.1007/s12035-024-04569-8/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12143123

Fields of Study

Neurotransmitter Receptor Influence on BehaviorTreatment of Major DepressionTryptophan and brain disordersMedicinePsychology03 medical and health sciences0302 clinical medicineAnimalsMaleMethylphenidateSelective Serotonin Reuptake InhibitorsVilazodone HydrochlorideCorpus StriatumRats, Sprague-DawleySerotonin 5-HT1 Receptor AgonistsDynorphinsReceptor, Serotonin, 5-HT1AAdministration, OralAntidepressive AgentsRats

MeSH Terms

Vilazodone HydrochlorideAdministration, OralAnimalsAntidepressive AgentsCorpus StriatumDrug SynergismDynorphinsGene Expression RegulationMaleMethylphenidateRats, Sprague-DawleySelective Serotonin Reuptake InhibitorsReceptor, Serotonin, 5-HT1ARatsSerotonin 5-HT1 Receptor Agonists

Keywords

MethylphenidateFluoxetineDynorphinAntidepressantPharmacologyPsychologyStriatumSerotoninCitalopramAgonistSerotonin reuptake inhibitorMedicineInternal medicineDopamineNeuroscienceAttention deficit hyperactivity disorderOpioidPsychiatryAnxietyReceptorOpioid peptideMaleVilazodone HydrochlorideAdministration, OralSerotonin 5-HT1 Receptor AgonistsDynorphinsCorpus StriatumAntidepressive AgentsRatsRats, Sprague-DawleyReceptor, Serotonin, 5-HT1AAnimalsSelective Serotonin Reuptake InhibitorsGene ExpressionPsychostimulantSSRIVilazodone

Sustainable Development Goals

SDG 0: Good health and well-being